この記事は最初に2025年10月2日に英語で公開されました
スプルーソン＆ファーガソンによる、過去1年間におけるオーストラリアの医薬品特許法に関する主要な動向の評論へようこそ。
この記事は最初に2025年10月2日に英語で公開されました
スプルーソン＆ファーガソンによる、過去1年間におけるオーストラリアの医薬品特許法に関する主要な動向の評論へようこそ。
Welcome to Spruson & Ferguson’s review of the most notable developments in Australian pharmaceutical patent law in the past year.
The year has seen a series of landmark decisions from...
Welcome to Spruson & Ferguson’s review of the most notable developments in Australian pharmaceutical patent law in the past...
Welcome to Spruson & Ferguson’s wrap-up of the most notable developments in pharmaceutical patent law in Australia in 2023. The past year saw a number of important Federal Court...
Welcome to Spruson & Ferguson’s wrap-up of the most notable developments in pharmaceutical patent law in Australia in 2023....
A recent decision of the Federal Court of Australia has demonstrated that the launch of a pharmaceutical product by a generic company even after expiry of the standard term...
A recent decision of the Federal Court of Australia has demonstrated that the launch of a pharmaceutical product by...